Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...

Changing the mechanism of action may offer more durable disease control for patients with PsA who do not respond to an initial TNF inhibitor.

CalciMedica’s stock nosedived after the biotech abandoned a phase 2 study of its calcium release-activated calcium (CRAC) ...

Remibrutinib, a BTK inhibitor, offers a new oral treatment for chronic spontaneous urticaria, providing an alternative to traditional therapies. Experts discuss groundbreaking therapies in dermatology ...

ACE inhibitor use was associated with reduced all cause mortality in idiopathic pulmonary fibrosis in a matched real world ...

The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.

A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a ...

In certain patients, JAK inhibitor rescue medications seem to be more effective, researche ...

Corvus Pharmaceuticals, Inc. shares are up on solid soquelitinib AD phase 1 data: 75% hit EASI 75 at 200 mg BID, many ...

Sources of error that may lead to false association include PPI use shortly before diagnosis, short-term PPI use.